Table 4 Association between methylation status of P16 and TP53 and EC prognosis.

From: The relationship between P16INK4A and TP53 promoter methylation and the risk and prognosis in patients with oesophageal cancer in Thailand

Variable

Cases (%)

Median survival (Months)

(95% CI)

Crude HR

(95% CI)

p-value

Adjust HR (95% CI)

p-value

P16 Methylation status

Unmethylated P16

22 (20.9%)

20.2 (4.95–15.34)

1.00

0.013

1.00

0.027

Methylated P16

83 (79.1%)

8.5 (6.83–10.17)

2.28 (1.10–4.71)

 

2.82 (1.13–5.06)

 

TP53 Methylation status

Unmethylated TP53

28 (26.7%)

14.8 (4.85–24.75)

1.00

0.002

1.00

0.007

Methylated TP53

77 (73.3%)

8.4 (6.52–10.28)

2.37 (1.28–4.37)

 

2.95 (1.34–5.47)

 
  1. Oesophageal cancer; (95% CI): 95% confidence interval, HR hazard ratio, P16: (cyclin-dependent kinase inhibitor 2A), TP53: (tumour protein p53), adjust for age, gender, BMI, histology type, grading, TNM state, metastasis, complication and comorbidity by using Cox proportional hazards regression models. p-value from partial likelihood ratio test.
Back to article page